The landscape of metabolic pathway dependencies in cancer cell lines

Abstract

The metabolic reprogramming of cancer cells creates metabolic vulnerabilities that can be therapeutically targeted. However, our understanding of metabolic dependencies and the pathway crosstalk that creates these vulnerabilities in cancer cells remains incomplete. Here, by integrating gene expression data with genetic loss-of-function and pharmacological screening data from hundreds of cancer cell lines, we identified metabolic vulnerabilities at the level of pathways rather than individual genes. This approach revealed that metabolic pathway dependencies are highly context-specific such cancer cells are vulnerable to inhibition of one metabolic pathway only when activity of another metabolic pathway is altered. Notably, we also found that the no single metabolic pathway was universally essential, suggesting that cancer cells are not invariably dependent on any metabolic pathway. In addition, we confirmed that cell culture medium is a major confounding factor for the analysis of metabolic pathway vulnerabilities. Nevertheless, we found robust associations between metabolic pathway activity and sensitivity to clinically approved drugs that were independent of cell culture medium. Lastly, we used parallel integration of pharmacological and genetic dependency data to confidently identify metabolic pathway vulnerabilities. Taken together, this study serves as a comprehensive characterization of the landscape of metabolic pathway vulnerabilities in cancer cell lines.

Metabolic profiling reveals metabolic features of consolidation therapy in pediatric acute lymphoblastic leukemia

“…Plasma metabolomic profiling provides a snapshot of metabolic changes [35], which are a good choice for the investigation on diseases and responses to treatment [36]. We identified 3 metabolic pathways that were significantly altered by HDMTX.…”

Construction of an Amino Acid Metabolism-Related Prognostic Model for Colorectal Adenocarcinoma Patients

“…This is primarily due to the mounting body of evidence highlighting the aberrant metabolic pro les present in tumors. Such dysregulated metabolism not only fuels tumor cell proliferation, recurrence, and metastasis, but also exerts in uence over the immunosuppressive attributes and malignant characteristics of tumors [27][28][29] . As metabolomics research continues to advance, an increasing number of studies have underscored the value of identifying metabolic alterations in patients as a means for early screening across various malignancies, including colon cancer [30][31][32] .…”

Metabolomics paves the way for improved drug target identification

“…Another question left unanswered is how media composition might impact drug target identification by metabolomics. In mammalian cells, media composition can significantly affect the response to drugs and genetic perturbations (Joly et al , 2021). As such, would the authors have found different results if their yeast had been cultured in a different media?…”